The discovery focuses on disrupting the function of a certain protein complex that cancer cells, including leukemia cells, ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Three patients also had a complete remission but without higher white blood cell counts, known as a complete remission ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Received FDA guidance in a Type B meeting, on the registrational path for INB-100 in AML, an allogeneic gamma-delta T cell ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

Autolus Therapeutics ( (AUTL)) has provided an update. Autolus Therapeutics plc has achieved FDA approval for AUCATZYL®, a treatment for relapsed and refractory B-cell acute lymphoblastic leukemia, ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

At the age of 30, Nicholas Filtz was diagnosed with a rare form of cancer, and on this Veterans Day, he is sharing his cancer ...